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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of removing peripheral IV catheters when clinically indicated compared with removing and re-siting the catheter
routinely.
B A C K G R O U N D
Among hospitalised patients, intravenous therapy is themost com-
mon invasive procedure. It is associated with a phlebitis rate of
between 2.3% and 60% (White 2001; Gupta 2007) and an intra-
venous catheter-related bacteraemia rate of approximately 0.8%
(Maki 1991). Current guidelines recommend that peripheral in-
travenous catheters should be re-sited every 72 to 96 hours to re-
strict infection potential (O,Grady 2002), and most hospitals fol-
low this recommendation. The most recent guidelines state “re-
place peripheral venous catheters at least every 72 to 96 hours in
adults to prevent phlebitis” (p.762) and carries a category rating of
1B (strongly recommended for implementation and supported by
some experimental, clinical or epidemiological studies). However,
the guideline cites only one study to support the recommendation.
This was a paper published in 1998 and based on data collected
in 1998 (Lai 1998). Since then, there have been improvements in
catheter design and composition and more recent studies indicate
that the recommendation may need to be revised.
Description of the condition
Peripheral vein infusion thrombophlebitis is characterized by pain,
erythema (reddening, swelling, and palpable thrombosis of the
cannulated vein (Monreal 1999). Diagnosis remains controver-
sial and a number of grading systems have been proposed, in-
cluding the Maddox scale (Maddox 1977) and the Baxter scale
(Panadero 2002), which rank infusion thrombophlebitis accord-
ing to the severity of clinical signs and symptoms. The scales are
limited because not all symptoms may be present or they may not
always be present in the clusters described in the scales. Conse-
quently,many investigators define peripheral vein infusion throm-
bophlebitis based on two or more of the following: pain, tender-
ness, warmth, erythema (redness of the skin), swelling, and a palpa-
ble cord (Maki 1991;Monreal 1999). Although the precise patho-
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genesis of thrombus formation remains unclear it is thought to be
related to inflammation of the vein wall. Studies have been unable
to demonstrate a high correlation between phlebitis and catheter
infection and Maki has suggested that phlebitis may be primarily
a physical response ((Maki 1991). This was supported by Catney
and colleagues when investigating the aetiology of phlebitis; they
found that drug irritation, size of catheter and the person inserting
the catheter were all predictors (Catney 2001). Utrasonographic
imaging has demonstrated thrombus formation in two thirds of
catheterised veins studied and it has been suggested that catheter
design may be implicated (Everitt 1997). Thus, possible causes
of phlebitis are mechanical irritation from the catheter and the
properties of the infusate or intravenous (IV) administered medi-
cations.
Description of the intervention
The intervention under consideration is replacing an intravenous
peripheral catheter only if there are clinical indications to do so.
Clinical indications include blockage, pain, redness, infiltration,
swelling, leakage and phlebitis.
How the intervention might work
Each time skin integrity is breached, a potential portal for
pathogens is provided. For example, Uslusoy (2008) found a sig-
nificant relationship between the number of times infusions were
started and phlebitis (Uslusoy 2008). There is also some support
for this relationship from observational studies that have com-
pared outcomes between cannulas remaining in situ for varying
periods. In an adequately powered observational study, which in-
cluded patients from medical wards and intensive care units, the
investigators were unable to demonstrate any increased risk for
phlebitis beyond the second day (Bregenzer 1998). Similarly, in a
retrospective study of 784 IV starts, the rate of phlebitis on days
one and two was 11.5% dropping to 3.9% by day four (Homer
1998). The authors concluded that “there appeared to be less risk
in continuing therapy beyond the third day than re-starting the
therapy” (pp304). Catney 2001 also failed to demonstrate any in-
crease in phlebitis rates with the passage of time with failure rates
being less at 144 hours (1.9%) than at 72 hours (2.5%) Catney
2001. Similarly, in a prospective investigation of 305 peripheral
catheters there were 10 cases of infusion phlebitis amongst patients
who had their catheter in situ for less than 72 hours, whereas none
were reported in patients where the dwell time was longer (White
2001). In the same study, there were three cases of post-infusion
phlebitis; these all occured amongst patients whose peripheral vein
infusion catheter had been in place for less than 72 hours. Even
among a high risk population of oncology and infectious diseases
patients, phlebitis rates were no different when length of cannu-
lation was dichotomised to three days or less and more than three
days (Cornely 2002).
Why it is important to do this review
These observational studies create uncertainty around the CDC
guidelines relating to peripheral intravenous catheter manage-
ment. This has led some hospitals to adopt the practice of re-sit-
ing only where there is evidence of inflammation or infiltration
(personal communication). Making the guidelines even more dif-
ficult to rationalise is the recommendation for peripheral catheter
replacement in children, which states “do not replace peripheral
catheters unless clinically indicated” (CDC,15; pp761). This rec-
ommendation was based on several studies using dwell times of
intravenouus catheters of greater than 72 hours (Catney 2001;
Cornely 2002; Shimandle 1999). Insertion of a peripheral intra-
venous catheter can be a painful and traumatic process and, if
unneccessary, adds not only to patient’s discomfort but also has
significant cost implications for the institution. There is a clear
need to provide direction for clinicians through systematically re-
viewing existing studies.
O B J E C T I V E S
To assess the effects of removing peripheral IV catheters when clin-
ically indicated compared with removing and re-siting the catheter
routinely.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing routine removal of
peripheral IV catheterswith removal onlywhen clinically indicated
will be considered.
Types of participants
Any patient requiring a peripheral IV catheter to be in situ for at
least three days for the administration of intermittent or continu-
ous therapy (this may include patients in hospitals, nursing homes
or in community settings).
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Types of interventions
Any duration of routine replacement versus clinically indicated
replacement will be included.
Types of outcome measures
Primary outcomes
• Thrombophlebitis (using any definition identified by the
trial author).
• Cost (in terms of materials and labour associated with IV
catheter-related insertion). This may be unavailable in some
reports so cost is not an inclusion criteria.
Secondary outcomes
• Infiltration (defined as permeation of IV fluid into the
interstitial compartment, causing swelling of the tissue around
the site of the catheter).
• Catheter occlusion (identified by the inability to infuse
fluids).
• Number of catheter re-sites.
• IV-related sepsis (localised or systemic).
• Mortality.
• Pain.
• Satisfaction.
Search methods for identification of studies
Electronic searches
The Cochrane Peripheral Vascular Diseases (PVD) Group will
search their Trials Register and the Cochrane Central Register of
Controlled Trials (CENTRAL) in The Cochrane Library for publi-
cations describing randomised controlled trials of routine periph-
eral IV replacement compared with replacement based on clinical
indications. The PVD Group’s Trials Register is compiled from
electronic searches ofMEDLINE (1950 to date), EMBASE (1980
to date), and CINAHL (1982 to date), and through handsearch-
ing relevant journals.
The full list of journals that have been handsearched, as well
as the search strategies used to search databases are described
in the editorial information about the Cochrane PVD Group
in The Cochrane Library http://www.mrw.interscience.wiley.com/
cochrane/clabout/articles/PVD/frame.html.
The review authors will search the Cochrane Central Register of
Controlled Trials (CENTRAL), (The Cochrane Library, latest is-
sue) using the strategy described in Appendix 1 and MEDLINE
(1950 to current) using the search strategy described in Appendix
2.
Searching other resources
We will contact researchers and manufacturers in order to obtain
any unpublished data. Reference lists of potentially useful articles
will also be searched.We will also use ’Google’ to search the world
wide web for other relevant articles.
There will be no restriction on language.
Data collection and analysis
Selection of studies
Titles and abstracts identified through the search process will be
independently reviewed by JW and SO. Full reports of all poten-
tially relevant trials will be retrieved for further assessment of eli-
gibility based on the inclusion criteria. Differences of opinion will
be settled by consensus or referral to a third reviewer. There will
be no blinding of authorship.
Data extraction and management
Two review authors will independently assessed the quality of el-
igible trials, using the PVD quality assessment criteria outlined
below. Disagreements between review authors will be resolved by
consensus or referral to a third reviewer. We will contact investi-
gators of included trials to resolve any ambiguities.
Assessment of risk of bias in included studies
Adequacy of the randomisation process
A - Adequate sequence generation is reported for example, using
random number tables, computer random number generator, coin
tossing or card shuffling.
B - did not specify on the adequate reported methods in (A) but
mentioned randomisation method.
C - Other method of allocation that may not be random.
Adequacy of allocation concealment
A - Adequate: allocation concealment described that would not
allow investigators /participants to know or influence intervention
group before eligible participant entered in the study, for exam-
ple central randomisation, serially numbered, opaque, sealed en-
velopes.
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B - Unclear: unclearly concealed trials in which the author either
did not report allocation concealment approach at all, or reported
an approach that was not clearly adequate.
C - Inadequate: inadequately concealed trials in which themethod
of allocation is not concealed, such as alternation methods or un-
sealed envelopes; any information in the study that indicated that
investigators or participants could influence intervention group.
Blinding
A - Blinding of treatment providers: Yes/No/Unclear.
B - Blinding of participants: Yes/No/Unclear.
C - Blinding of outcome assessor: Yes/No/Unclear.
D - Blinding of data analysis: Yes/No/Unclear.
Intention-to-treat analysis (ITT)
A - Yes: Specifically reported by authors that ITT was undertaken
and this was confirmed on study assessment, or not
stated but evident form study assessment that ITTwas undertaken.
B - Unclear: Described as ITT analysis but unable to confirm on
study assessment, or not reported and unable to
confirm by study assessment.
C - No: Lack of ITT analysis confirmed on study assessment, for
example patients who were randomised were not
included in the analysis because they did not receive the study
intervention, or they withdrew from the study, or
were not included because of protocol violation, regardless of
whether ITT reported or not.
Completeness of follow up
Percentage of participants for whomdatawas completed at defined
study end-point.
Measures of treatment effect
For individual trials, effect measures for categorical outcomes will
include relative risk (RR) with its 95% confidence interval (CI).
For statistically significant effects, number needed to treat (NNT),
or number needed to harm (NNH), will be calculated. For contin-
uous outcomes, the effect measure will be mean difference (MD)
or, if the scale of measurement differs across trials, standardized
mean difference (SMD), each with its 95% CI. For any meta-
analyses (see below), for categorical outcomes the typical estimates
of RR with their 95% CI will be calculated; and for continuous
outcomes the weighted mean difference (WMD) or a summary
estimate for SMD, each with its 95% CI, will be calculated.
Data will be analysed using The Cochrane Collaboration’s Review
Manager (RevMan) 5 software.
Unit of analysis issues
We do not anticipate any unit of analysis issues. Cross-over trials
are not eligible. Cluster randomised trials are not expected in this
field. It is possible that one patient may experience more than
one episode of thrombophlebitis (or other outcome) during the
period of study. We plan to analyse the data as the proportion of
participants having one or more episodes.
Dealing with missing data
If some outcome data remain missing despite our attempts to
obtain complete outcome data from authors, we will perform an
available-case analysis, based on the numbers of patients for whom
outcome data are known. If standard deviations are missing, we
will impute them them from other studies or, where possible,
compute them from standard errors using the formula SD = SE X√
N , where these are available Higgins 2008.
Assessment of heterogeneity
Heterogeneitywill be assessed visually andby using the chi-squared
statistic with significance being set at P < 0.10. In addition, the
degree of heterogeneity will be investigated by calculating the I2
statistic Higgins 2008. If evidence of significant heterogeneity is
identified (> 50%), we will explore potential causes and a random-
effects approach to the analysis will be used.
Assessment of reporting biases
Reporting biaswill be assessed using guidelines inCochraneHand-
book for Systematic Reviews of Interventions Higgins 2008.
Data synthesis
Where appropriate, results of comparable trials will be pooled
using a fixed-effect model and the pooled estimate together with
its 95% CI will be reported. We will conduct a narrative review of
eligible studies where statistical synthesis of data from more than
one study is not possible or considered not appropriate.
Subgroup analysis and investigation of heterogeneity
We plan to analyse potential sources of heterogeneity using the
following subgroup analyses:
1. Type of randomisation (truly randomised versus not
reported).
2. Concealment of allocation (adequate versus not reported).
3. Blinding (patients and clinicians blinded versus open-label).
4. Statement of withdrawals and losses to follow up in each
group (stated versus not stated).
5. Intermittent versus continuous infusion.
4Clinically indicated replacement versus routine replacement of peripheral venous catheters (Protocol)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sensitivity analysis
We will perform sensitivity analyses to explore the effect of the
following criteria:
1. Concealment of allocation.
2. Size of studies (< 100 patients versus at least 100 patients).
3. Duration of follow up.
4. Unpublished studies (if any).
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A P P E N D I C E S
Appendix 1. Central search strategy
#1 MeSH descriptor PHLEBITIS exp. trees 1, 2 and 3
#2 phlebitis in All Text
#3 thrombophlebitis in All Text
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor INFUSIONS, intravenous
#6 intravenous infusion* in All Text
#7 peripheral vein infusion* in All Text
#8 peripheral intravenous catheter* OR PICs in All Text
#9 peripheral IVs in All Text
#10 catherization indwelling in All Text
#11 intravenous peripheral cannula* in All Text
#12 peripheral venous canula* in All Text
#13 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #12)
#14 (#4 AND #13)
Appendix 2. MEDLINE search strategy
#1 MeSH PHLEBITIS exp.
#2 MeSH THROMBOPHLEBITIS
#3 phlebitis in All Fields
#4 periphlebitis in All Fields
#5 thrombophlebitis in All Fields
#6 (#1 OR #2 OR#3 OR #4 OR #5)
#7 MeSH INFUSIONS, intravenous
#8 MeSH CATHERIZATION, peripheral
#9 intravenous infusion* in All Fields
#10 peripheral venous catheter* in All Fields
#11 peripheral intravenous catheter* OR PIC
#12 peripheral IVs in All Fields
#13 intravenous peripheral cannula* in All Fields
#14 peripheral venous canula* in All Fields
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#15 peripheral vein infusion* in All Fields
#16 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17 MeSH RANDOMIZED CONTROLLED TRIAL.pt.
#18 MeSH RANDOMIZED CONTROLLED TRIALS.topic
#19 MeSH CONTROLLED CLINICAL TRIAL .pt.
#20 MeSH RANDOM ALLOCATION
#21 MeSH DOUBLE-BLIND METHOD
#22 MeSH SINGLE-BLIND METHOD
#23 MeSH PLACEBOS
#24 MeSH CLINICAL TRIALS exp
#25 random* ti,ab
#26 placebo* ti,ab
#27 MeSH COMPARATIVE STUDY
#28 (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #26 OR #27)
#29 (#6 AND #16 AND #28)
H I S T O R Y
Protocol first published: Issue 2, 2009
C O N T R I B U T I O N S O F A U T H O R S
JW conceived the idea for the review. JW and SO wrote the protocol and JH wrote the search strategy.
JW will search for and select trials, assess methodological quality of trials, extract and enter data, analyse the results and draft the final
review.
SO will search for trials, arbitrate on the selection of trials, interpret the analysis and draft the final review.
JH will comment on the draft review.
CR will select trials for inclusion, extract data, check data entry, interpret the analysis and comment on the draft review.
D E C L A R A T I O N S O F I N T E R E S T
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